Warning letter
RLC Labs Inc.: warning letter of Oct 9, 2020
FDA warning letter 607596 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 607596 |
|---|---|
| Company | RLC Labs Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Oct 9, 2020 |
| Posted date | Oct 20, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 211.100(a), 207, 211.34, 312, 211.22(a), 211.84(d)(2), 211.166(a), 600.3(h)(6) |
| Inspection city | Phoenix |
| Inspection ZIP | 85034-6703 |
| Inspection start date | Feb 20, 2020 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: